Calling all startups with synthetic biology solutions — there's a new venture capital firm looking to invest in you.

Veronica Wu has announced the launch of First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups.

“Synthetic Biology aims to take parts of natural biology systems to produce organisms/cells/biological systems with novel or enhanced characteristics. It sits at the convergence of technology and biology, and provides us a powerful tool to address some of the biggest challenges humanity faces, like cancer/incurable diseases, sustainability and climate change," Wu says in a news release.

Wu has over 20 years of experience in managerial positions at tech companies like Apple, Tesla, and Motorola, and she served as a founding team member of McKinsey & Company’s Greater China office's business technology practice.

As an investor, Wu has funded 300 early-stage tech companies in the past six years. She's seen her portfolio companies reach major accomplishments, including 34 unicorns, six SPACs, and four IPOs to date, per the release.

She's betting on synthetic biology by launching First Bight Ventures — the first and only VC firm completely devoted to this field. The firm has already struck up a partnership with Ginkgo Bioworks, a leading synthetic biology platform provider.

"The potential applications are far reaching in scope as well as impact.” Wu says. “Presently, we stand at a significant inflection point. Synthetic Biology is to 2022 what the ‘.com’ era was to the 90s.”

Wu is a relative newcomer to Houston. She made the move from Silicon Valley to the Bayou City in the middle of 2021. She plans to leverage Houston's market to incubate these startups locally, according to the release.

“Houston is well positioned to become a major center for synthetic biology with its existing talent, industries, and capital," she says.